Quotient Bioresearch Acquires Edinburgh Clinical Research Facility from Charles River Laboratories and Forms Quotient Clinical, a New Strategic Business UnitQuotient Bioresearch, a leading provider of drug development services, announced its acquisition of Charles River Laboratories’ Edinburgh clinical research facility. The two companies will form a new strategic business unit called Quotient Clinical. Quotient's announcement was featured in Genetic Engineering & Biotechnology News (GEN), an integrated media publication covering industry news through features, tutorials and essays. GEN has an impressive 143,000 unique monthly visitors, resulting in Quotient's story being widely read by a relevant audience. In addition, the piece of coverage included links to Quotient's and Charles River Laboratories’ websites, which could help to drive relevant traffic to both sites.
CoverageGenetic Engineering & Biotechnology News (GEN)
Genetic Engineering & Biotechnology News (GEN) is an integrated media publication, available in both print and online. GEN produces 21 issues of its magazine per year and it's comprehensive coverage includes industry-standard tutorials and technical articles in bio-processing, essays, news on drug discovery, feature articles on emerging technologies, product roundups and reports from key scientific and industry meetings. GEN reaches over 176,000 Scientists worldwide and has 59,534 BPA-qualified subscribers. 96% of GEN subscribers are actively involved in driving the technology valuation and purchasing process.